Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?

Cancer chemotherapy and pharmacology - 1 Jul 2010

Ishii Yukimoto, Suzuki Shigeru, Takahashi Yasuo, Takayama Tadatoshi, Asai Satoshi

Abstract excerpt

PURPOSE: S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0.4:1. CYP2A6 genetic polymorphism and dihydropyrimidine dehydrogenase (DPD) inhibition are important for the antitumor effect of S-1. Exploiting the usefulness of the 2-(13)C-uracil breath test (UrBT) as an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Breath Tests

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2A6

Share to Drug Combinations

Share to Gas Chromatography-Mass Spectrometry

Share to Neoplasm Recurrence, Local

Share to Radiopharmaceuticals

Share to Uracil

Source

Identifiers

PMID: 19921195
DOI: 10.1007/s00280-009-1168-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?PMID 19921195Read ↗

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.Semantic proximity Read ↗

[The influence of CYP2A6 polymorphism on adjuvant S-1 chemotherapy outcomes in patients with curatively resected gastric cancer].Semantic proximity Read ↗

(13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients.Semantic proximity Read ↗

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.Semantic proximity Read ↗

Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.Semantic proximity Read ↗

A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.Semantic proximity Read ↗

Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.Semantic proximity Read ↗

Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.Semantic proximity Read ↗

Breath tests to phenotype drug disposition in oncology.Semantic proximity Read ↗

The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.Semantic proximity Read ↗

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.Semantic proximity Read ↗

5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.